Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
CEACAM5 Drugs Market Outlook: Rising Cancer Cases and Clinical Trials to Fuel…
Key Takeaways from the CEACAM5 Market Report Key Takeaways from the CEACAM5 Market Report Discover which therapies are expected to grab the CEACAM5 drugs market share @CEACAM5 Drugs Market Report CEACAM5 Drugs Market Dynamics The CEACAM5 drugs market is rapidly evolving due to the molecule's significance in the treatment of various cancers, particularly colorectal, gastric, and non-small cell lung cancers. One of the primary drivers of the CEACAM5 drugs market is the...
PR Newswire
17/09/2024
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with…
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1 ,2 Kisqali ®(ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety profile seen across all subgroups in pivotal Phase III NATALEE trial, including patients with...
Nasdaq GlobeNewswire
17/09/2024
EssilorLuxottica unveils plans for its new corporate headquarters in Paris
EssilorLuxottica unveils plans for its new corporate headquarters in ParisParis, France (September 17, 2024)– EssilorLuxottica announced today the signing of a long-term pre-letting agreement for its new global headquarters in Paris, expected to open late 2027. Located at Place Valhubert, in the heart of the lively Austerlitz district -Paris 13e-, boasting a tech startup and global digital company scene, the new headquarters will bring together in a single building up to more than...
Nasdaq GlobeNewswire
17/09/2024
Moose Knuckles Unveils Full Fall/Winter 2024 Collection, Featuring Dennis…
Campaign Highlights: Campaign Highlights: FromCarlos Nazario, Global Artistic Director:"The complete Fall/Winter 2024 collection represents the culmination of our vision for Moose Knuckles – a perfect blend of sophistication, functionality, and bold style. Working withDennis Rodmanhas been incredible; his fearless approach to fashion and life embodies everything the brand stands for. Paired with Amelia's return, we're showcasing the versatility and appeal of Moose Knuckles to a...
PR Newswire
17/09/2024
Idorsia continues to further the science of sleep and insomnia with new…
Allschwil, Switzerland – September 17, 2024Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults with chronic insomnia, will be presented at Sleep Europe 2024 – the 27th Congress of the European Sleep Research Society (ESRS), taking place in Seville, Spain, September 24–27, 2024.The following posters will be presented: Lederer K, et al. Efficacy and safety of daridorexant in patients...
Nasdaq GlobeNewswire
17/09/2024
Crossject to report first-half 2024 financial results and host webcast on…
Dijon, France, 17 September, 2024 - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®,will report its financial results for the six months ended June 30, 2024, as scheduled on Monday, September 23. In addition, at 18:00 CET that day, CEO Patrick Alexandre will provide a commentary on the company's strategic priorities during a webcast and be available for...
Nasdaq GlobeNewswire
17/09/2024
Human Microbiome Market to Hit USD 4,206 Million by 2030 with 31.5% CAGR |…
Browse in-depth TOC on "Human Microbiome Market"250 - Tables50 - Figures300 - Pages Browse in-depth TOC on "Human Microbiome Market" 250 - Tables 50 - Figures 300 - Pages Drivers of Growth The surge in the human microbiome market is largely driven by collaborative research efforts between the microbiome industry and academia, as well as the rise of start-ups and SMEs venturing into the microbiome sector. These smaller entities are attracting major investments thanks to…
PR Newswire
17/09/2024
Healthcare Staffing Market is expected to generate a revenue of USD 89.12…
The healthcare staffing industry is undergoing transformative changes, with increasing reliance on temporary, travel, and per-diem staffing to meet the ever-growing demand for qualified healthcare workers. Our report delves into key trends, including technological advancements, regulatory shifts, and the evolving landscape of workforce solutions. The healthcare staffing industry is undergoing transformative changes, with increasing reliance on temporary, travel, and per-diem staffing to meet...
PR Newswire
17/09/2024
Pharmaceutical Drug Delivery Market to Hit USD 2,546 Billion by 2029 |…
Browse in-depth TOC on "Pharmaceutical Drug Delivery Market"907 - Tables63 - Figures718 - Pages Browse in-depth TOC on "Pharmaceutical Drug Delivery Market" 907 - Tables 63 - Figures 718 - Pages Injectable Drug Delivery Sector Leading the Market Injectable drug delivery holds the largest market share among administration routes, primarily due to its effectiveness in managing chronic diseases. Injectables offer advantages over oral medications by improving patient adherence...
PR Newswire
17/09/2024
CSL Joins Accumulus Synergy to Drive Industry Change
Following the launch of Accumulus Synergy's innovative cloud-based information exchange platform, CSL joins the nonprofit industry association "We are honored to welcome CSL to our member community,” commented Frank Nogueira, Accumulus Chief Executive Officer. “A membership with Accumulus is an investment in the ecosystem. We closely engage with national regulatory agencies (NRAs), trade associations, life sciences organizations, and non-governmental organizations (NGOs) within the…
Nasdaq GlobeNewswire
17/09/2024
Zoetis to Introduce First Cartridge-Based AI-Powered Haematology Analyser
Abhay Nayak, President of Global Diagnostics at Zoetis said: "This latest innovation further strengthens our haematology story, particularly when partnered with Vetscan Imagyst® AI Blood Smear – reinforcing the existing capabilities of Zoetis' Virtual Laboratory portfolio to provide a comprehensive and connected platform." Abhay Nayak, President of Global Diagnostics at Zoetis said: "This latest innovation further strengthens our haematology story, particularly when partnered with…
PR Newswire
17/09/2024
Independent Expert Assessment Validates RenovaroCube's Potential as a…
Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess...
Nasdaq GlobeNewswire
17/09/2024
Zoetis to Debut AI-Powered Haematology Technology at London Vet Show
Abhay Nayak, President of Global Diagnostics at Zoetis, said: "This latest innovation further strengthens our haematology story, particularly when partnered with Vetscan Imagyst® AI Blood Smear – reinforcing the existing capabilities of Zoetis' Virtual Laboratory portfolio to provide a comprehensive and connected platform." Abhay Nayak, President of Global Diagnostics at Zoetis, said: "This latest innovation further strengthens our haematology story, particularly when partnered…
PR Newswire
17/09/2024
Respiree teams up with Roche Diagnostics in APAC to introduce a new simplified…
By the first quarter of 2025, Respiree will team up with Roche to launch pilot programs across APAC that offer a simplified approach to patient monitoring by combining Roche's cobas® pulse system with Respiree's vital sign monitoring. The solution is also expected in future to integrate machine learning models that predict clinical deterioration using historical data with risk scores at the bedside. By the first quarter of 2025,Respireewill team up with Roche to launch pilot programs...
PR Newswire
17/09/2024
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
BOSTON and LONDON, Sept.17, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the appointment of Rob Bazemore, experienced life sciences leader, to the Akari Board of Directors effective September 17, 2024. “I am very honored to have the opportunity to work with this distinguished board of directors to advance the portfolio opportunities,” said Mr. Bazemore...
Nasdaq GlobeNewswire
17/09/2024
ClariMed Inc. Expands Strategy & Advisory Services in Europe with New Director…
"I'm thrilled to join ClariMed at this exciting time. The company's vision aligns perfectly with my passion for advancing healthcare through human-centered design," Collinson said. "I look forward to leveraging my experience to help our clients navigate the complex regulatory landscape while driving user-centered innovation in the MedTech industry." "I'm thrilled to join ClariMed at this exciting time. The company's vision aligns perfectly with my passion for advancing…
PR Newswire
17/09/2024
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b…
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's DiseasePrescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in SeptemberPotentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic ADFDA Fast Track designation granted in July for ACI-35.030 (now “JNJ-2056”) for AD Lausanne, Switzerland, September 17, 2024– AC...
Nasdaq GlobeNewswire
17/09/2024
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1…
MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of BioNTech's “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Tuesday, October 1 st, 2024 in London, United Kingdom. The event will provide an overview of BioNTech's and InstaDeep's AI strategy and capabilities, and the application of AI in BioNTech's pipeline and...
Nasdaq GlobeNewswire
17/09/2024
Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of…
Read Asieris' full media release here: https://asieris.com/asieris-unveils-results-for-the-first-time-at-2024-pdtpd-conference-the-efficacy-data-of-non-surgical-treatment-of-cervical-hsil-with-apl-1702-in-reducing-the-histological-grade-of-cervical-preca/ Read Asieris' full media release here:...
PR Newswire
17/09/2024
Ureteral Access Sheath Market to Reach $2.2 Billion, Globally, by 2033 at 5.5%…
Prime determinants of growth Prime determinants of growth The global ureteral access sheath market is witnessing notable growth due to surge in cases of kidney stones. Kidney stones, or renal calculi, are crystalline mineral deposits that form within the kidneys or urinary tract, posing significant health risks and causing debilitating pain. This surge in prevalence is attributed to various factors, including dietary habits, sedentary lifestyles, dehydration, and metabolic disorders...
PR Newswire
17/09/2024
RESOURCE-SAVING INNOVATION: MAMMUT LOOPINSULATION
From concept to innovation From concept to innovation The development of Loopinsulation began after an analysis of Mammut's carbon footprint in 2018, which revealed that 13% of the company's CO 2emissions came from rope manufacturing. In response, Mammut conducted extensive research on repurposing...
PR Newswire
17/09/2024
Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation…
"The granting of this patent represents a significant achievement in our research and development efforts," said Jenny Barnett, Chief Executive Officer of Monument Therapeutics. "MT1980's innovative approach to targeting neuroinflammation positions us at the cutting edge of therapeutic advancement in psychiatry and neurology. We believe this compound has the potential to address significant unmet medical needs and our team is excited to advance MT1980 through the next stages of…
PR Newswire
17/09/2024
Safe Life completes acquisition of Medisol in Europe
Medisol, headquartered in the Netherlands, is one of the premier European distributors of AEDs with substantial expertise in eCommerce and operations across 30 European countries. This acquisition strategically complements Safe Life's existing portfolio, positioning us to effectively serve markets throughout North America and all of Europe. Medisol, headquartered inthe Netherlands, is one of the premier European distributors of AEDs with substantial expertise in eCommerce and operations...
PR Newswire
17/09/2024
MinervaX and Wacker Biotech Announce Manufacturing Collaboration for…
MinervaX's lead vaccine candidate, is a novel protein-only vaccine, based on fusions of highly immunogenic and proactive protein domains from selected surface proteins of GBS. The company is strongly committed and dedicated to advancing its novel vaccine and has successfully completed two Phase II clinical trials of its maternal vaccine against GBS and is in preparation to commence Phase III clinical trials in this indication. Data from MinervaX's GBS vaccine is very positive, demonstrating an…
PR Newswire
17/09/2024
Altri Comunicati